Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - MYRIAD GENETICS INC | mygn-ex321_6.htm |
EX-31.2 - EX-31.2 - MYRIAD GENETICS INC | mygn-ex312_7.htm |
EX-31.1 - EX-31.1 - MYRIAD GENETICS INC | mygn-ex311_8.htm |
EX-10.2 - EX-10.2 - MYRIAD GENETICS INC | mygn-ex102_187.htm |
10-Q - 10-Q - MYRIAD GENETICS INC | mygn-10q_20170930.htm |
Exhibit 10.1
Attachment
Each of the following executive officers of Myriad Genetics, Inc. has entered into the Company’s standard form Executive Retention Agreement.
Executive Officer |
Execution Date |
Mark C. Capone, President and Chief Executive Officer |
November 17, 2006, as amended October 12, 2007, and further amended September 29, 2015 |
Alexander Ford, President, Myriad Genetic Laboratories, Inc. |
July 1, 2015, as amended September 29, 2015 |
Gary A. King, EVP International Operations |
July 8, 2010, as amended September 29, 2015 |
Jerry S. Lanchbury, Ph.D., Chief Scientific Officer |
February 17, 2005, as amended October 12, 2007, and further amended September 29, 2015 |
Richard M. Marsh, Esq., EVP, General Counsel and Secretary |
February 17, 2005, as amended October 12, 2007, and further amended September 29, 2015 |
Ralph L. McDade, President, Myriad RBM, Inc. |
September 29, 2015 |
R. Bryan Riggsbee, Chief Financial Officer and Treasurer |
December 18, 2014, as amended September 29, 2015 |
Bernard F. Tobin, President, Crescendo Biosciences, Inc. |
December 19, 2014, as amended September 29, 2015 |
Mark Verratti, President, Assurex Health, Inc. |
September 19, 2017 |